New Combined Drug Regimen for Complete Cure of Pulmonary Tuberculosis in Patient with Impaired Hepatocellular Functioning – A Case Report
International Journal of TROPICAL DISEASE & Health,
The research gives new therapeutic regimen to Tuberculosis. Despite of the fact being that the current regimen is a burden on liver functioning; most of these are highly hepatotoxic and increases serum alanine aminotransferase (ALT) manifolds. In the backdrop of such a condition this clinical study has been done. Here 4 drugs has been selected and TB infection of a middle aged female patient was cured rapidly in one month who had hepatocellular changes. The regimen in this research has also showed significant improvement of liver functions post-therapy. This is about the “Mumbai Protocol” of tuberculosis management.
- Mycobacterium tuberculosis
- Mumbai protocol
- infection therapy
How to Cite
LiverTox: Clinical and research information on drug-induced liver injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Ethambutol. [Updated 2020 Dec 24].
Ramappa V, Aithal GP. Hepatotoxicity related to anti-tuberculosis Drugs: Mechanisms and management. Journal of Clinical and Experimental Hepatology. 2013;3(1):37–49.
Waters M, Tadi P. Streptomycin. [Updated 2022 Jul 11]. In: Stat Pearls [Internet]. Treasure Island (FL): Stat Pearls Publishing; 2022.
Liver Tox: Clinical and research information on drug-induced liver injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Streptomycin. [Updated 2021 Sep 15].
LiverTox: Clinical and research information on drug-induced liver injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Cycloserine. [Updated 2017 Nov 3].
Zhang T, Jiang G, Wen S, Huo F, Wang F, Huang H, Pang Y. Para-aminosalicylic acid increases the susceptibility to isoniazid in clinical isolates of Mycobacterium tuberculosis. Infection and Drug Resistance. 2019;12:825–829. Available:https://doi.org/10.2147/IDR.S200697
Zheng J, Rubin EJ, Bifani P, Mathys V, Lim V, Au M, Jang J, Nam J, Dick T, Walker JR, Pethe K, Camacho LR. Para-aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis. The Journal of Biological Chemistry. 2013;288(32):23447–23456.
Hershfield ES. Tuberculosis - Still a major health problem. The Canadian Journal of Infectious Diseases. 1991;2(4):131–132.
Essentials of medical pharmacology. KD Tripathi. 8th edition; Chapter-56, Antitubercular Drugs. 2018:819-820.
Zhao H, Wang Y, Zhang T, Wang Q, Xie W. Drug-induced liver injury from anti-tuberculosis treatment: A retrospective cohort study. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research. 2020;26:e920350. Available:https://doi.org/10.12659/MSM.920350
Abstract View: 187 times
PDF Download: 31 times